89 related articles for article (PubMed ID: 20732753)
61. Identification and verification of PRDX1 as an inflammation marker for colorectal cancer progression.
Chu G; Li J; Zhao Y; Liu N; Zhu X; Liu Q; Wei D; Gao C
Am J Transl Res; 2016; 8(2):842-59. PubMed ID: 27158373
[TBL] [Abstract][Full Text] [Related]
62. Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma.
Trzeciecka A; Klossowski S; Bajor M; Zagozdzon R; Gaj P; Muchowicz A; Malinowska A; Czerwoniec A; Barankiewicz J; Domagala A; Chlebowska J; Prochorec-Sobieszek M; Winiarska M; Ostaszewski R; Gwizdalska I; Golab J; Nowis D; Firczuk M
Oncotarget; 2016 Jan; 7(2):1717-31. PubMed ID: 26636537
[TBL] [Abstract][Full Text] [Related]
63. Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma.
Fushimi F; Taguchi K; Izumi H; Kohno K; Kuwano M; Ono M; Nakashima Y; Takesue T; Naito S; Oda Y
Virchows Arch; 2013 Oct; 463(4):553-62. PubMed ID: 23907567
[TBL] [Abstract][Full Text] [Related]
64. The conformational bases for the two functionalities of 2-cysteine peroxiredoxins as peroxidase and chaperone.
König J; Galliardt H; Jütte P; Schäper S; Dittmann L; Dietz KJ
J Exp Bot; 2013 Aug; 64(11):3483-97. PubMed ID: 23828546
[TBL] [Abstract][Full Text] [Related]
65. P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.
Chen MB; Wu XY; Yu R; Li C; Wang LQ; Shen W; Lu PH
PLoS One; 2012; 7(9):e45388. PubMed ID: 23049793
[TBL] [Abstract][Full Text] [Related]
66. Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer.
Zhang B; Wang K; He G; Guan X; Liu B; Liu Y; Bai Y
J Cancer Res Clin Oncol; 2012 Apr; 138(4):621-6. PubMed ID: 22215146
[TBL] [Abstract][Full Text] [Related]
67. High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma.
Zheng L; Xie G; Duan G; Yan X; Li Q
PLoS One; 2011; 6(7):e22203. PubMed ID: 21765952
[TBL] [Abstract][Full Text] [Related]
68. Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation.
Gao MC; Jia XD; Wu QF; Cheng Y; Chen FR; Zhang J
Acta Pharmacol Sin; 2011 Apr; 32(4):528-36. PubMed ID: 21468086
[TBL] [Abstract][Full Text] [Related]
69. Tailoring treatment of rectal adenocarcinoma: immunohistochemistry for predictive biomarkers.
Kapur P
Anticancer Drugs; 2011 Apr; 22(4):362-70. PubMed ID: 21233707
[TBL] [Abstract][Full Text] [Related]
70. [Predictive and prognostic factors for the chemoradiotherapy of rectal cancer].
Karasawa K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():509-15. PubMed ID: 22214013
[No Abstract] [Full Text] [Related]
71. Role of peroxiredoxin I in rectal cancer and related to p53 status.
Chen MF; Lee KD; Yeh CH; Chen WC; Huang WS; Chin CC; Lin PY; Wang JY
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):868-78. PubMed ID: 20732753
[TBL] [Abstract][Full Text] [Related]
72. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment.
Chen MF; Chen WC; Wu CT; Lin PY; Shau H; Liao SK; Yang CT; Lee KD
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1461-72. PubMed ID: 17084559
[TBL] [Abstract][Full Text] [Related]
73. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.
Spitz FR; Giacco GG; Hess K; Larry L; Rich TA; Janjan N; Cleary KR; Skibber JM
Clin Cancer Res; 1997 Oct; 3(10):1685-90. PubMed ID: 9815551
[TBL] [Abstract][Full Text] [Related]
74. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
75. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression.
Chen MF; Keng PC; Shau H; Wu CT; Hu YC; Liao SK; Chen WC
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):581-91. PubMed ID: 16414373
[TBL] [Abstract][Full Text] [Related]
76. Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma--relation to radiotherapy response and survival.
Friesland S; Mellin H; Munck-Wikland E; Nilsson A; Lindholm J; Dalianis T; Lewensohn R
Anticancer Res; 2001; 21(1B):529-34. PubMed ID: 11299799
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
